CIK 0001006281 · Non-accelerated filer<br>Smaller reporting company
Protalix BioTherapeutics, Inc.
Sign in to watch- Ticker
- PLX
- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 650643773
- Phone
- 201-696-9345
- Business address
- 2 UNIVERSITY PLAZA, SUITE 100, HACKENSACK, NJ, 07601
- Former names
- ORTHODONTIX INC, EMBASSY ACQUISITION CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 82 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-03 | Schwartz Aharon Director | Grant or award · Stock Options (Right to Buy) | +17,000 | 17,000 | ||
| 2026-09-03 | Schwartz Aharon Director | Grant or award · Restricted Stock Units | +8,500 | 8,500 | ||
| 2026-09-03 | Elze Christian Director | Grant or award · Stock Options (Right to Buy) | +17,000 | 17,000 | ||
| 2026-09-03 | Elze Christian Director | Grant or award · Restricted Stock Units | +8,500 | 8,500 | ||
| 2026-09-03 | Ben Zvi Shmuel Director | Grant or award · Stock Options (Right to Buy) | +17,000 | 17,000 | ||
| 2026-09-03 | Ben Zvi Shmuel Director | Grant or award · Restricted Stock Units | +8,500 | 8,500 | ||
| 2026-09-03 | Forster Eliot Director | Grant or award · Stock Options (Right to Buy) | +17,000 | 17,000 | ||
| 2026-09-03 | Forster Eliot Director | Grant or award · Restricted Stock Units | +8,500 | 8,500 | ||
| 2026-09-03 | Bashan Dror PRESIDENT AND CEO | Grant or award · Stock Option (Right to Buy) | +320,000 | 320,000 | ||
| 2026-09-03 | Bashan Dror PRESIDENT AND CEO | Grant or award · Restricted Stock Units | +160,000 | 160,000 | ||
| 2026-09-03 | Naos Yaron Sr. VP & COO | Grant or award · Stock Option (Right to Buy) | +112,000 | 112,000 | ||
| 2026-09-03 | Naos Yaron Sr. VP & COO | Grant or award · Restricted Stock Units | +56,000 | 56,000 | ||
| 2026-09-03 | Melincoff Gwen A Director | Grant or award · Stock Options (Right to Buy) | +17,000 | 17,000 | ||
| 2026-09-03 | Melincoff Gwen A Director | Grant or award · Restricted Stock Units | +8,500 | 8,500 | ||
| 2026-09-03 | Boudes Pol F Director | Grant or award · Stock Options (Right to Buy) | +17,000 | 17,000 | ||
| 2026-09-03 | Boudes Pol F Director | Grant or award · Restricted Stock Units | +8,500 | 8,500 | ||
| 2026-09-03 | Bar-Shalev Amos Director | Grant or award · Stock Options (Right to Buy) | +17,000 | 17,000 | ||
| 2026-09-03 | Bar-Shalev Amos Director | Grant or award · Restricted Stock Units | +8,500 | 8,500 | ||
| 2025-12-19 | Bashan Dror PRESIDENT AND CEO | Purchase | +56,000 | $1.81 | $101K | 188,516 |
| 2025-11-18 | Bar-Shalev Amos Director | Sale | −168 | $1.87 | $314 | 0 |
Page 1 of 7 · 139 trades